Improving Delivery of Early Treatment to Influenza-Infected Patients

Clinical Infectious Diseases

Volumn 66, Issue 7, 2018, Pages 1042-1044

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diagnosis; Influenza; Oseltamivir; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT;

ANTIGEN DETECTION; ANTIVIRAL THERAPY; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HIGH RISK PATIENT; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; INFLUENZA; NOTE; NUCLEIC ACID AMPLIFICATION; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL RESPIRATORY TRACT INFECTION; INFLUENZA A VIRUS (H1N1); SEASON; UNITED STATES;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; OUTPATIENTS; SEASONS; UNITED STATES;

EID: 85044182212     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix924     Document Type: Note

References (13)

1. Aoki FY, Macleod MD, Paggiaro P, et al; IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-9.
2. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729-37.
3. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207:553-63.
4. Venkatesan S, Myles PR, Leonardi-Bee J, et al. Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1) pdm09 at high risk of hospitalization: an individual participant data metaanalysis. Clin Infect Dis 2017; 64:1328-34.
5. Ison MG. Contemporary influenza diagnostics: renewed focus on testing patients. Ann Intern Med 2017; 167:438-9.
6. Lee N, Ison MG. Editorial commentary. Late treatment with neuraminidase inhibitors for severely ill patients with influenza: better late than never? Clin Infect Dis 2012; 55:1205-8.
7. Stewart RJ, Flannery B, Chung JR, et al. Influenza antiviral prescribing for outpatients with an acute respiratory illness and at high risk for influenza-associated complications during 5 influenza seasons-United States, 2011-2016. Clin Infect Dis 2018; 66:1035-41.
8. Havers F, Thaker S, Clippard JR, et al. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. Clin Infect Dis 2014; 59:774-82.
9. Biggerstaff M, Jhung MA, Reed C, Fry AM, Balluz L, Finelli L. Influenza-like illness, the time to seek healthcare, and influenza antiviral receipt during the 2010-2011 influenza season-United States. J Infect Dis 2014; 210:535-44.
10. Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:3234-40.
11. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-72.
12. Merckx J, Wali R, Schiller I, et al. Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis. Ann Intern Med 2017; 167:394-409.
13. Bruning AHL, Leeflang MMG, Vos JMBW, et al. Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis. Clin Infect Dis 2017; 65:1026-32.